Immunic, Inc. (NASDAQ:IMUX) Shares Acquired by Millennium Management LLC

Millennium Management LLC increased its stake in shares of Immunic, Inc. (NASDAQ:IMUX - Free Report) by 480.6% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 579,683 shares of the company's stock after buying an additional 479,846 shares during the period. Millennium Management LLC owned 0.64% of Immunic worth $580,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in IMUX. Invesco Ltd. acquired a new stake in Immunic in the fourth quarter valued at about $37,000. Barclays PLC acquired a new stake in Immunic during the 4th quarter worth about $84,000. Bridgeway Capital Management LLC lifted its position in shares of Immunic by 11.5% during the 4th quarter. Bridgeway Capital Management LLC now owns 215,000 shares of the company's stock valued at $215,000 after acquiring an additional 22,200 shares during the period. Renaissance Technologies LLC increased its stake in Immunic by 45.6% in the fourth quarter. Renaissance Technologies LLC now owns 566,623 shares of the company's stock valued at $567,000 after purchasing an additional 177,542 shares in the last quarter. Finally, 683 Capital Management LLC boosted its position in shares of Immunic by 2.2% during the 4th quarter. 683 Capital Management LLC now owns 700,000 shares of the company's stock worth $700,000 after purchasing an additional 15,349 shares in the last quarter. Institutional investors and hedge funds own 51.82% of the company's stock.

Immunic Stock Performance

IMUX stock traded down $0.03 during trading on Thursday, hitting $0.84. 1,047,212 shares of the company's stock traded hands, compared to its average volume of 878,836. Immunic, Inc. has a 52 week low of $0.56 and a 52 week high of $2.11. The business has a fifty day simple moving average of $0.95 and a 200 day simple moving average of $1.04. The stock has a market capitalization of $80.86 million, a price-to-earnings ratio of -0.69 and a beta of 1.48.

Immunic (NASDAQ:IMUX - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The company reported ($0.25) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.25). Research analysts forecast that Immunic, Inc. will post -0.94 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently commented on IMUX. HC Wainwright reissued a "buy" rating and issued a $10.00 price objective on shares of Immunic in a research note on Thursday, May 1st. D. Boral Capital reaffirmed a "buy" rating and issued a $10.00 price target on shares of Immunic in a report on Thursday, June 5th. William Blair restated an "outperform" rating on shares of Immunic in a research report on Friday, May 16th. B. Riley reiterated a "buy" rating and issued a $5.00 price objective (down from $6.00) on shares of Immunic in a report on Friday, May 23rd. Finally, Wall Street Zen downgraded Immunic from a "hold" rating to a "sell" rating in a research report on Thursday, March 20th. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $11.60.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.